Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 35
5.523,04 S&P · 23,48 Vola-Index · 94.302,41 BTC · 1,13637 EURUSD
System-State: Number of processed items 39.386 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US29405E2081
State: 26.04.2025 | 12PM
Do you already know our new terminal view? Click here.
FIGI: BBG00P83FXJ0
ENVB
Enveric Biosciences, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Enveric Biosciences, Inc.
ISIN
US29405E2081
TICKER
ENVB
MIC
XNAS
REUTERS
ENVB.OQ
BLOOMBERG
ENVB US
Mon, 31.03.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update following the filing of its 10-K on Friday March 28, 2025 which reported fin...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 17.03.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring®, which is being held in Milan, Italy, March 17-1...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 06.03.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company will build on its recent business development momentum by soliciting Requests-For-...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 27.02.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., CEO and Director, has issued a Letter to Shareholders to provide an...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 25.02.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439 (the ‘439...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 04.02.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that its wholly-owned subsidiary, Akos Biosciences, Inc. (“Akos”), has entered into two...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 03.02.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the closing of its previously announced public offering of an aggregate of 1,666,666 sha...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Fri, 31.01.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 30.01.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark O...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 06.01.2025       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Ass...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 02.12.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued two U.S. Patents, Nos. 1...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 25.11.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small molecule therapeutics for the treatment of depression, anxiety, and other psychiatric disorders, today announced the completion of preclinical pharmacokinetic (“PK”) studies in rat and dog furthe...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 14.11.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the third quarter ended September 30, 202...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 12.11.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company has executed a licensing agreement with MycoMedica Life Sciences, out-lic...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.10.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced positive results for preclinical safety and pharmacology studies, which evaluated off-target i...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Thu, 26.09.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it is presenting research describing the Company’s identification of EB-003 as its lead d...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Wed, 25.09.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that research highlighting the Company’s lead compound, EB-003, is being presented at the 7th ...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.09.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference being ...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Tue, 13.08.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Aries Science & Technology (“Aries”), a developer of encapsulation technologies, today announced that Patent No. 12,059,393 was issued on August 13, 2024, to Enveric’...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink
Mon, 12.08.2024       Enveric Biosciences
US29405E2081

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. ...
Read More
Enveric Biosciences
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.